The Department of Defense today awarded Ellume USA $231.8 million to ramp up domestic production of its COVID-19 diagnostic test, the first test users can perform fully at home without a prescription. The agency expects the contract to increase daily domestic production of the test by 640,000 by December.

The contract also will procure 8.5 million of the tests for U.S. distribution. The Food and Drug Administration recently authorized emergency use of the test, which can detect the SARS-CoV-2 virus in a nasal swab sample and report the results via a smartphone app. 

Related News Articles

Headline
A study published Oct. 30 by the American Heart Association found that people have an elevated risk of heart attack and stroke following flu and COVID-19…
Headline
The Centers for Disease Control and Prevention will update its immunization schedules for the COVID-19 and chickenpox vaccines to adopt recent recommendations…
Headline
The Food and Drug Administration today issued a request for public comment on a series of questions regarding current approaches to evaluating artificial…
Headline
The Food and Drug Administration yesterday announced that Olympus issued a global recall of its ViziShot 2 FLEX needles manufactured prior to May 12 following…
Headline
The Advisory Committee on Immunization Practices Sept. 19 recommended that patients should consult their health care provider if they want to receive a COVID-…
Headline
The Department of Health and Human Services Sept. 18 announced it will take new actions to help improve care for individuals with long COVID. They include a…